Demand in healthcare rests on a different foundation than in most industries: it does not depend on consumer confidence or the business cycle, but on the slow evolution of population age structure, chronic disease incidence and access to care. This demand rarely contracts because of short-term macroeconomic swings, but it also rarely surges — it accumulates over years, and returns show up on the same timescale. This feature shapes how business models differ across segments of the industry, and what kind of capital is suited to participating in it.
Industry structure: three distinct commercial logics
Healthcare is not a single industry but a set of at least three coexisting commercial logics. In-vitro diagnostics and medical devices resemble precision manufacturing: once a product clears regulatory registration, it can be produced and sold at scale, with revenue tied directly to volume and installed base, and risk concentrated in the pace of technology iteration and channel penetration. Drug development follows an entirely different pattern — moving from early research to launch requires multiple rounds of clinical trials, the great majority of candidate pipelines terminate along the way, and the handful of successes must cover the failure cost of the whole portfolio, a probability-driven model in which winners are highly concentrated. Hospital and care-delivery operations form a third logic, with revenue structure constrained by reimbursement policy and the regional distribution of medical resources, expanding more slowly than the first two.
Each logic makes different demands on capital: diagnostics and devices suit conventional evaluation grounded in operating metrics, drug development requires a dedicated pipeline risk framework, and hospital and service operations call for a longer-horizon judgment about regional resources and policy relationships. Conflating the three is a common starting point for misjudgment among capital entering healthcare from outside the sector.
Risk profiles: diagnostics/devices versus drug development
In-vitro diagnostic products
Registration pathways are comparatively well defined, failure probability is lower, and revenue accumulates steadily with installed base and test volume rather than depending on any single breakout product.
Early-stage innovative drug pipelines
A high share of candidates terminate across multiple trial rounds, and success concentrates returns heavily in individual products; portfolio-style exposure is a common way of managing this risk.
Medical device consumables
Failure probability sits close to diagnostics, but returns from any single product are also relatively dispersed; outcomes depend more on channel coverage and the establishment of clinical habit.
Established blockbuster drugs
Failure risk drops sharply after launch, but value depends heavily on lifecycle management of the existing product and the remaining span of patent protection, with returns concentrated in a small number of products.
Top-left: In-vitro diagnostic products; Top-right: Early-stage innovative drug pipelines; Bottom-left: Medical device consumables; Bottom-right: Established blockbuster drugs
Hospital procurement and channel realities
However strong a product is on its own merits, hospital procurement remains an unavoidable gate. Equipment and consumables procurement at public hospitals typically runs through centralized tendering, with long decision cycles and multiple participants; a product must first enter a procurement catalog before it can reach any specific hospital. Adjustments to reimbursement catalogs move on a similarly slow, annual rhythm, directly shaping pricing room and the pace at which volume can build. Technical superiority does not automatically translate into commercial leadership — channel building, clinical relationships and compliance capability are equally decisive in whether a product actually reaches the doctors and patients it is designed for.
This reality also explains why first-mover advantage is unusually durable in healthcare: once a product category establishes clinical usage habit and a position within procurement catalogs, a later entrant with comparable technical specifications still needs several years to rebuild that same channel position from scratch.
Balancing innovation against reimbursement discipline
The industry's long-term trajectory is not simply about technical breakthroughs, but a continual recalibration between innovative capacity and payer discipline.
Continued domestic substitution
Domestic diagnostic and device products already hold a cost and responsiveness edge in mid- and lower-tier markets, and are gradually extending into more technically demanding categories.
Centralized procurement reshaping pricing
Large-scale centralized procurement continues to compress unit pricing in certain mature categories, pushing companies to shift growth focus toward new categories and differentiated products.
Penetration into grassroots care
The migration of diagnostic equipment into grassroots healthcare institutions is a clear trend, but it imposes requirements on ease of use and maintenance cost that differ from tertiary-hospital settings.
Payer emphasis on real-world evidence
Public and commercial insurers increasingly rely on real-world outcome data, not registration trial results alone, when assessing new products for coverage.
Patient capital's advantage across long product cycles
The path from registration to channel maturity often takes three to five years or longer, a cycle that sits in natural tension with capital under pressure to recycle quickly. Capital investing on its own account, without a fixed horizon, is better suited to accompanying a company through this cycle — supporting it through registration and early ramp without pressing for near-term results, and remaining patient while channel position and clinical habit are still being established. This is not a preference specific to healthcare so much as a requirement that the industry's own product cycle places on the nature of the capital involved.
The Havrion Capital Perspective
Our attention in healthcare concentrates on diagnostics and devices rather than drug development pipelines, a choice that follows directly from the risk-profile difference described above: the commercial logic of diagnostics and devices tracks verifiable operating growth more closely, and fits more naturally with capital invested on our own account over a long holding period, while the probability-driven pattern of drug pipelines typically calls for dedicated, portfolio-level risk management — a risk structure we do not seek to carry within a single investment.
We similarly weigh a company's established position within hospital procurement and compliance systems more heavily than short-term leadership on any one generation of technical specifications. Regulatory clearance is only a starting point; what determines long-term value is whether a company can keep entering procurement catalogs, build durable clinical relationships, and hold pricing power as payer discipline tightens. Judgments of this kind require time to verify, and the patience that our own long-term capital can offer is the principal comparative advantage we bring to this industry.